SCHEMBL6177499

SCHEMBL6177499

O=C1Nc2ccc(Br)c(Cl)c2C1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 12/20 0.67
TGM2 P21980 5/20 0.43
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
DUSP3 P51452 1/20 0.38
BLM P54132 1/20 0.38
PTPN5 P54829 1/20 0.38
KMT2A Q03164 1/20 0.38
PTPN11 Q06124 1/20 0.38
MCL1 Q07820 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
BCHE P06276 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
MAOA P21397 3/20 0.36
MAOB P27338 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31103242 1.00 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL22711532 0.85 CES1 (0.47) CES1TGM2
SCHEMBL10173048 0.85 CES1 (0.47) CES1TGM2
SCHEMBL734955 0.80 CES1 (1.00) CES1TGM2MEN1POLBMAPT
SCHEMBL31728330 0.78 CES1 (0.48) CES1TGM2MEN1POLBMAPT
SCHEMBL29446052 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL19260393 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL5738366 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL2372330 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL3391317 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11466016-B2 Pharmaceutical compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-10-11 US disclosed
US-20210107908-A1 PHARMACEUTICAL COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-04-15 US disclosed
CN-111902415-A Pharmaceutical compounds 大冢制药株式会社 2020-11-06 CN disclosed
US-10479765-B2 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-11-19 US disclosed
US-10189788-B2 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-29 US disclosed
US-20190002409-A1 SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-03 US disclosed
US-20170260140-A1 SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS Bayer Pharma Aktiengesekkschaft (DE) 2017-09-14 US disclosed
EP-1105376-B1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMA (JP) 2005-02-09 EP disclosed
US-6576656-B1 Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2003-06-10 US disclosed
EP-1105376-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-13 EP disclosed
WO-2000010975-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2000-03-02 WO disclosed
EP-0002624-B1 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1981-10-14 EP disclosed
EP-0002624-A1 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479765-B2 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents AADAC, NFKBIA, NOD2 CES1 289/4885TGM2 566/4885MEN1 4414/4885
US-20210107908-A1 PHARMACEUTICAL COMPOUNDS MAPT, CYP3A5, SLC5A1 CES1 2734/4885TGM2 1793/4885MEN1 188/4885
US-20170260140-A1 SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS AADAC, NFKBIA, NOD2 CES1 289/4885TGM2 566/4885MEN1 4414/4885
US-20190002409-A1 SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS AADAC, NFKBIA, NOD2 CES1 289/4885TGM2 566/4885MEN1 4414/4885
US-10189788-B2 Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents AADAC, NFKBIA, NOD2 CES1 289/4885TGM2 566/4885MEN1 4414/4885
US-11466016-B2 Pharmaceutical compounds MAPT, CYP3A5, SLC5A1 CES1 2734/4885TGM2 1793/4885MEN1 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.